Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Non-Current Debt (2016 - 2021)

BioRestorative Therapies (BRTX) has disclosed Non-Current Debt for 11 consecutive years, with $250000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Non-Current Debt fell 94.15% year-over-year to $250000.0, compared with a TTM value of $250000.0 through Dec 2021, down 94.15%, and an annual FY2021 reading of $250000.0, down 94.15% over the prior year.
  • Non-Current Debt was $250000.0 for Q4 2021 at BioRestorative Therapies, down from $5.8 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $5.8 million in Q3 2021 and bottomed at $61686.0 in Q3 2017.
  • Average Non-Current Debt over 5 years is $896994.8, with a median of $227951.0 recorded in 2021.
  • The sharpest move saw Non-Current Debt surged 1830.6% in 2018, then tumbled 94.15% in 2021.
  • Year by year, Non-Current Debt stood at $194282.0 in 2017, then skyrocketed by 169.66% to $523894.0 in 2018, then crashed by 70.0% to $157143.0 in 2019, then surged by 2617.42% to $4.3 million in 2020, then crashed by 94.15% to $250000.0 in 2021.
  • Business Quant data shows Non-Current Debt for BRTX at $250000.0 in Q4 2021, $5.8 million in Q3 2021, and $220589.0 in Q2 2021.